Patients’ characteristics at diagnosis
| . | Total . | CALR+ (A) . | JAK2V617F+ (B) . | MPLW515+ (C) . | CALR, JAK2, MPL wild type (D) . | P A vs B . | P A vs C . | P A vs D . |
|---|---|---|---|---|---|---|---|---|
| Number of patients, (%) | 1150* | 164 (14) | 736 (64) | 44 (4) | 198 (17) | |||
| Gender M/F, n (%) | 403/739 (35/65) | 84/80 (51/49) | 266/470 (36/64) | 13/31 (30/70) | 40/158 (20/80) | <.0001 | .010 | <.0001 |
| Age, years, median (5th-95th percentile) | 57.6 (27-82) | 53.5 (27-81) | 60.8 (28-83) | 59.7 (27-87) | 47.8 (21-78) | .001 | .396 | .245 |
| Hemoglobin, g/dL, median (5th-95th percentile) | 14.1 (11.8-16.3) | 13.7 (11.6-16.1) | 14.5 (11.9-16.4) | 13.4 (11.6-16.0) | 13.6 (11.7-15.8) | <.0001 | .681 | .099 |
| Hematocrit, %, median (5th-95th percentile) | 43.0 (36.0-48.8) | 42.1 (35.6-47.6) | 43.7 (37.2-49.3) | 41.8 (35.0-48.5) | 41.0 (35.1-47.0) | .002 | .880 | .133 |
| White blood cell count, ×109/L, median (5th-95th percentile) | 8.7 (5.4-14.7) | 7.8 (5.2-12.0) | 9.0 (5.7-15.1) | 7.9 (4.8-14.0) | 8.4 (5.3-14.0) | <.0001 | .725 | .034 |
| Platelet count, ×109/L, median (5th-95th percentile) | 718 (486-1313) | 842 (551-1769) | 704 (490-1234) | 834 (544-1700) | 647 (464-1318) | <.0001 | .971 | <.0001 |
| CV risk factors, n (%) | 568 (50) | 71 (43) | 386 (52) | 27 (61) | 84 (42) | .034 | .033 | .868 |
| Smoke, n (%) | 98 (9) | 7 (4) | 66 (9) | 5 (11) | 20 (10) | .046 | .073 | .035 |
| Diabetes, n (%) | 107 (9) | 11 (7) | 77 (10) | 5 (11) | 14 (7) | .143 | .303 | .892 |
| Hypertension, n (%) | 459 (40) | 59 (36) | 314 (43) | 21 | 65 | .116 | .497 | .175 |
| Previous major thrombosis, n (%) | 167 (15) | 13 (8) | 122 (17) | 9 (20) | 23 (12) | .005 | .016 | .243 |
| IPSET score, n (%) | <.0001 | <.0001 | .124 | |||||
| Low risk, n (%) | 263 (23) | 110 (67) | 0 (0) | 17 (39) | 136 (69) | |||
| Intermediate risk, n (%) | 316 (28) | 48 (29) | 206 (28) | 16 (36) | 46 (23) | |||
| High risk, n (%) | 563 (49) | 6 (4) | 530 (72) | 11 (25) | 16 (8) |
| . | Total . | CALR+ (A) . | JAK2V617F+ (B) . | MPLW515+ (C) . | CALR, JAK2, MPL wild type (D) . | P A vs B . | P A vs C . | P A vs D . |
|---|---|---|---|---|---|---|---|---|
| Number of patients, (%) | 1150* | 164 (14) | 736 (64) | 44 (4) | 198 (17) | |||
| Gender M/F, n (%) | 403/739 (35/65) | 84/80 (51/49) | 266/470 (36/64) | 13/31 (30/70) | 40/158 (20/80) | <.0001 | .010 | <.0001 |
| Age, years, median (5th-95th percentile) | 57.6 (27-82) | 53.5 (27-81) | 60.8 (28-83) | 59.7 (27-87) | 47.8 (21-78) | .001 | .396 | .245 |
| Hemoglobin, g/dL, median (5th-95th percentile) | 14.1 (11.8-16.3) | 13.7 (11.6-16.1) | 14.5 (11.9-16.4) | 13.4 (11.6-16.0) | 13.6 (11.7-15.8) | <.0001 | .681 | .099 |
| Hematocrit, %, median (5th-95th percentile) | 43.0 (36.0-48.8) | 42.1 (35.6-47.6) | 43.7 (37.2-49.3) | 41.8 (35.0-48.5) | 41.0 (35.1-47.0) | .002 | .880 | .133 |
| White blood cell count, ×109/L, median (5th-95th percentile) | 8.7 (5.4-14.7) | 7.8 (5.2-12.0) | 9.0 (5.7-15.1) | 7.9 (4.8-14.0) | 8.4 (5.3-14.0) | <.0001 | .725 | .034 |
| Platelet count, ×109/L, median (5th-95th percentile) | 718 (486-1313) | 842 (551-1769) | 704 (490-1234) | 834 (544-1700) | 647 (464-1318) | <.0001 | .971 | <.0001 |
| CV risk factors, n (%) | 568 (50) | 71 (43) | 386 (52) | 27 (61) | 84 (42) | .034 | .033 | .868 |
| Smoke, n (%) | 98 (9) | 7 (4) | 66 (9) | 5 (11) | 20 (10) | .046 | .073 | .035 |
| Diabetes, n (%) | 107 (9) | 11 (7) | 77 (10) | 5 (11) | 14 (7) | .143 | .303 | .892 |
| Hypertension, n (%) | 459 (40) | 59 (36) | 314 (43) | 21 | 65 | .116 | .497 | .175 |
| Previous major thrombosis, n (%) | 167 (15) | 13 (8) | 122 (17) | 9 (20) | 23 (12) | .005 | .016 | .243 |
| IPSET score, n (%) | <.0001 | <.0001 | .124 | |||||
| Low risk, n (%) | 263 (23) | 110 (67) | 0 (0) | 17 (39) | 136 (69) | |||
| Intermediate risk, n (%) | 316 (28) | 48 (29) | 206 (28) | 16 (36) | 46 (23) | |||
| High risk, n (%) | 563 (49) | 6 (4) | 530 (72) | 11 (25) | 16 (8) |
Eight patients with double positivity for JAK2V617F and MPLW515 were excluded from further analysis